EU set to launch full-scale in­ves­ti­ga­tion in­to Grail-Il­lu­mi­na deal amid an­titrust con­cerns — re­port

The pro­posed $8 bil­lion merg­er be­tween liq­uid biop­sy firm Grail and can­cer blood screen­ing gi­ant Il­lu­mi­na has met with noth­ing but flack since it was first an­nounced in Sep­tem­ber. Af­ter hit­ting waves in the US ear­li­er this year, the pact is now fac­ing a po­ten­tial­ly dev­as­tat­ing set­back in the EU as well.

The EU is pre­pared to launch a full-scale probe in­to a pend­ing merg­er be­tween Grail and Il­lu­mi­na that has evolved in­to Ex­hib­it A for in­ter­na­tion­al an­titrust ad­vo­cates’ case against non­com­pet­i­tive phar­ma M&A, sources close to the deal told Reuters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER